Page 17 - 2022-32-中国全科医学

·3982· http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn

Acta Neuropathol Commun，2019，7（1）：5. DOI：10.1186/ protein in neurology: a systematic review and meta-analysis［J］.
s40478-018-0649-3. JAMA Neurol，2019，76（9）：1035-1048. DOI：
［7］HÅKANSSON I，TISELL A，CASSEL P，et al. Neurofilament 10.1001/jamaneurol.2019.1534.
levels，disease activity and brain volume during follow-up in multiple ［19］AXELSSON M，SJÖGREN M，ANDERSEN O，et al.
sclerosis［J］. J Neuroinflammation，2018，15（1）：209. DOI： Neurofilament light protein levels in cerebrospinal fluid predict long-
10.1186/s12974-018-1249-7. term disability of Guillain-Barré syndrome: a pilot study［J］.
［8］DEISENHAMMER F，ZETTERBERG H，FITZNER B，et al. The Acta Neurol Scand，2018，138（2）：143-150. DOI：
cerebrospinal fluid in multiple sclerosis［J］. Front Immunol， 10.1111/ane.12927.
2019，10: 726. DOI：10.3389/fimmu.2019.00726. ［20］KUHLE J，BARRO C，ANDREASSON U，et al. Comparison
［9］KAPOOR R，SMITH K E，ALLEGRETTA M，et al. Serum of three analytical platforms for quantification of the neurofilament
neurofilament light as a biomarker in progressive multiple light chain in blood samples: ELISA，electrochemiluminescence
sclerosis［J］. Neurology，2020，95（10）：436-444. DOI： immunoassay and Simoa［J］. Clin Chem Lab Med，2016，54（10）：
10.1212/WNL.0000000000010346. 1655-1661. DOI：10.1515/cclm-2015-1195.
［10］MOMTAZMANESH S，SHOBEIRI P，SAGHAZADEH A，et al. ［21］ALTMANN P，DE SIMONI D，KAIDER A，et al. Increased serum
Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic neurofilament light chain concentration indicates poor outcome in
review and meta-analysis［J］. Rev Neurosci，2021，32（6）： Guillain-Barré syndrome［J］. J Neuroinflammation，2020，17（1）：
573-595. DOI：10.1515/revneuro-2020-0145. 86. DOI：10.1186/s12974-020-01737-0.
［11］FERREIRA-ATUESTA C，REYES S，GIOVANONNI G， ［22］MARTÍN-AGUILAR L，CAMPS-RENOM P，LLEIXÀ C，
et al. The evolution of neurofilament light chain in multiple et al. Serum neurofilament light chain predicts long-term prognosis
sclerosis［J］. Front Neurosci，2021，15: 642384. DOI： in Guillain-Barré syndrome patients［J］. J Neurol Neurosurg
10.3389/fnins.2021.642384. Psychiatry，2020：2020. DOI：10.1136/jnnp-2020-323899.
［12］SHAHIM P，TEGNER Y，MARKLUND N，et al. Neurofilament ［23］MATTSSON N，CULLEN N C，ANDREASSON U，et al.
light and tau as blood biomarkers for sports-related concussion［J］. Association between longitudinal plasma neurofilament light
N eur ology， 20 18 ， 90 （ 2 0） ： e17 80 - 1 788 . DO I ： and neurodegeneration in patients with alzheimer disease［J］.
10.1212/WNL.0000000000005518. JAM A Ne uro l ，2019，76（7）：791-799. DOI：
［13］THOMPSON A G B，LUK C，HESLEGRAVE A J，et al. 10.1001/jamaneurol.2019.0765.
Neurofilament light chain and tau concentrations are markedly ［24］VAGBERG M，NORGREN N，DRING A，et al. Levels and age
increased in the serum of patients with sporadic Creutzfeldt-Jakob dependency of neurofilament light and glial fibrillary acidic protein
disease，and tau correlates with rate of disease progression［J］. J in healthy individuals and their relation to the brain parenchymal
Neurol Neurosurg Psychiatry，2018，89（9）：955-961. DOI： fraction［J］. PLoS One，2015，10（8）：e0135886. DOI：
10.1136/jnnp-2017-317793. 10.1371/journal.pone.0135886.
［14］JOHNSON E B，BYRNE L M，GREGORY S，et al. Neurofilament ［25］KHALIL M，PIRPAMER L，HOFER E，et al. Serum
light protein in blood predicts regional atrophy in Huntington neurofilament light levels in normal aging and their association with
disease［J］. Neurology，2018，90（8）：e717-723. DOI： morphologic brain changes［J］. Nat Commun，2020，11（1）：
10.1212/WNL.0000000000005005. 812. DOI：10.1038/s41467-020-14612-6.
［15］EVERS K S，ATKINSON A，BARRO C，et al. Neurofilament as ［26］MILLERE E，ROTS D，SIMRÉN J，et al. Plasma neurofilament
neuronal injury blood marker in preeclampsia［J］. Hypertension， light chain as a potential biomarker in Charcot-Marie-Tooth
2018，71（6）：1178-1184. DOI：10.1161/HYPERTENSIONA disease［J］. Eur J Neurol，2021，28（3）：974-981. DOI：
HA.117.10314. 10.1111/ene.14689.
［16］GAETANI L，BLENNOW K，CALABRESI P，et al. Neurofilament ［27］WILLISON H J，JACOBS B C，VAN DOORN P A. Guillain-
light chain as a biomarker in neurological disorders［J］. J Neurol Barré syndrome［J］. Lancet，2016，388（10045）：717-727.
Neurosurg Psychiatry，2019，90（8）：870-881. DOI：10.1136/ DOI：10.1016/S0140-6736（16）00339-1.
jnnp-2018-320106. ［28］MARIOTTO S，FARINAZZO A，MAGLIOZZI R，et al. Serum
［17］LEE Y C，LEE B H，YIP W，et al. Neurofilament proteins as and cerebrospinal neurofilament light chain levels in patients with
prognostic biomarkers in neurological disorders［J］. Curr Pharm acquired peripheral neuropathies［J］. J Peripher Nerv Syst，
Des，2020，25（43）：4560-4569. DOI：10.2174/13816128256 2018，23（3）：174-177. DOI：10.1111/jns.12279.
66191210154535. ［29］GAIOTTINO J，NORGREN N，DOBSON R，et al. Increased
［18］BRIDEL C，VAN WIERINGEN W N，ZETTERBERG H， neurofilament light chain blood levels in neurodegenerative
et al. Diagnostic value of cerebrospinal fluid neurofilament light neurological diseases［J］. PLoS One，2013，8（9）：e75091.